Correction: Perivascular diffusion and white matter free water improve identification of cognitive impairment in cerebral small vessel disease - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Enhanced Identification of Cognitive Impairment in Cerebral Small Vessel Disease Through Perivascular Diffusion and White Matter Free Water

  • By

  • Chunhong Yang

  • Sunmei Cai

  • Bin Wang

  • Jie Zhou

  • Dongmei Wu

  • Muzi Li

  • Wenlu Geng

  • Lianshuang Wu

  • Kaiyue Peng

  • Yi Yang

  • Wenquan Gu

  • September 15, 2026

Share

Clinical Scorecard: Correction: Enhanced Identification of Cognitive Impairment in Cerebral Small Vessel Disease Through Perivascular Diffusion and White Matter Free Water

At a Glance

CategoryDetail
ConditionCognitive Impairment in Cerebral Small Vessel Disease
Key MechanismsPerivascular diffusion and white matter free water
Target PopulationPatients with cerebral small vessel disease
Care SettingNeurology

Key Highlights

  • Correction of grant identifier for the General Project
  • Clarification of funding sources
  • Impact of perivascular diffusion on cognitive impairment identification

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not specified

          Not specified

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Perivascular diffusion and white matter free water improve identification of cognitive impairment in cerebral small vessel disease

            • by Chunhong Yang, Sunmei Cai, Bin Wang, Jie Zhou, Dongmei Wu, Muzi Li, Wenlu Geng, Lianshuang Wu, Kaiyue Peng, Yi Yang, Wenquan Gu

            • September 15, 2026

            Related Content

            FDA approves first therapy for Alexander disease

            The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.

            Correction: Electroencephalographic power spectrum changes in cerebral small vessel disease combined with cognitive dysfunction and its relationship with neutrophil/lymphocyte ratio and its clinical value—A pilot study

            FDA approves FET-PET agent for glioma

            The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.